Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 26 of 26 entries
Sorted by: Best Match Show Resources per page
Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial.

JMIR research protocols

Birkeland K, Khandwalla RM, Kedan I, Shufelt CL, Mehta PK, Minissian MB, Wei J, Handberg EM, Thomson LE, Berman DS, Petersen JW, Anderson RD, Cook-Wiens G, Pepine CJ, Bairey Merz CN.
PMID: 29263019
JMIR Res Protoc. 2017 Dec 20;6(12):e255. doi: 10.2196/resprot.8057.

BACKGROUND: Digital wearable devices provide a "real-world" assessment of physical activity and quantify intervention-related changes in clinical trials. However, the value of digital wearable device-recorded physical activity as a clinical trial outcome is unknown.OBJECTIVE: Because late sodium channel inhibition...

Cite
Birkeland K, Khandwalla RM, Kedan I, et al. Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Res Protoc. 2017;6(12):e255doi: 10.2196/resprot.8057.
Birkeland, K., Khandwalla, R. M., Kedan, I., Shufelt, C. L., Mehta, P. K., Minissian, M. B., Wei, J., Handberg, E. M., Thomson, L. E., Berman, D. S., Petersen, J. W., Anderson, R. D., Cook-Wiens, G., Pepine, C. J., & Bairey Merz, C. N. (2017). Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR research protocols, 6(12), e255. https://doi.org/10.2196/resprot.8057
Birkeland, Kade, et al. "Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial." JMIR research protocols vol. 6,12 (2017): e255. doi: https://doi.org/10.2196/resprot.8057
Birkeland K, Khandwalla RM, Kedan I, Shufelt CL, Mehta PK, Minissian MB, Wei J, Handberg EM, Thomson LE, Berman DS, Petersen JW, Anderson RD, Cook-Wiens G, Pepine CJ, Bairey Merz CN. Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Res Protoc. 2017 Dec 20;6(12):e255. doi: 10.2196/resprot.8057. PMID: 29263019; PMCID: PMC5752966.
Copy Download .nbib Format: NLM
Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial).

The American journal of cardiology

Keeley EC, Li HJ, Cogle CR, Handberg EM, Merz CNB, Pepine CJ.
PMID: 34728061
Am J Cardiol. 2022 Jan 01;162:1-5. doi: 10.1016/j.amjcard.2021.09.015. Epub 2021 Oct 30.

Resolvins and maresins, members of the specialized proresolving mediator (SPM) family, are omega-3 fatty acid-derived lipid mediators that attenuate inflammation. We hypothesized that they play a role in the pathophysiology of coronary microvascular dysfunction (CMD) in women with ischemia...

Cite
Keeley EC, Li HJ, Cogle CR, et al. Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial). Am J Cardiol. 2021;162:1-5doi: 10.1016/j.amjcard.2021.09.015.
Keeley, E. C., Li, H. J., Cogle, C. R., Handberg, E. M., Merz, C. N. B., & Pepine, C. J. (2022). Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial). The American journal of cardiology, 1621-5. https://doi.org/10.1016/j.amjcard.2021.09.015
Keeley, Ellen C, et al. "Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial)." The American journal of cardiology vol. 162 (2022): 1-5. doi: https://doi.org/10.1016/j.amjcard.2021.09.015
Keeley EC, Li HJ, Cogle CR, Handberg EM, Merz CNB, Pepine CJ. Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial). Am J Cardiol. 2022 Jan 01;162:1-5. doi: 10.1016/j.amjcard.2021.09.015. Epub 2021 Oct 30. PMID: 34728061; PMCID: PMC8754056.
Copy Download .nbib Format: NLM
Showing 25 to 26 of 26 entries